Area of research
Immunology · Oncology
Research interest
Research focused on Adverse effect and Immunotherapy, with related work in Cancer immunotherapy, Nausea, Cancer. Notable publications include 'Tim-3 finds its place in the cancer immunotherapy landscape', 'Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors', and 'Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies'.
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
Tim-3 finds its place in the cancer immunotherapy landscape
Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.